EGFR and neoplasm: The oral EGFR tyrosine kinase inhibitor Erlotinib (Terceva, Roche, Mannheim, Germany) reversibly binds to the intracellular domain of EGFR and blocks autophosphorylation of EGFR with subsequent suppression of the downstream signaling pathways that causes uncontrolled tumor cell growth and proliferation.